Tag: daraxonrasib
-
FDA Approves Columbia-Backed Pancreatic Cancer Drug Daraxonrasib
Daraxonrasib, a new targeted therapy supported by Columbia research, has received FDA approval for pancreatic cancer, nearly doubling overall survival in metastatic patients and marking a significant breakthrough.
HealthScience & TechnologyBusinessEducationMedical ScienceEnvironmentArtificial IntelligenceEconomySocial IssuesAsia DaraxonrasibPancreatic CancerColumbia UniversityFDAOncologyClinical TrialsDrug Approvalnewsletter
-
Media Monitor: CBS Denies Joe Rogan '60 Minutes' Rumors; Pancreatic Cancer Drug Shows Promise
PolitiFact reports CBS News has debunked social media rumors about Joe Rogan joining "60 Minutes." It also highlights a clinical trial where an experimental pill nearly doubled pancreatic cancer patients' survival.
MediaHealth Joe RoganCBS News60 MinutesPancreatic CancerClinical TrialsDaraxonrasibMedical ResearchPolitiFact's Ellen Hine
-
Media Monitor: Pancreatic Cancer Drug Shows Promising Clinical Trial Results
The Washington Post is reporting that a new pill, daraxonrasib, has shown promising results in a clinical trial for pancreatic cancer, doubling patient survival compared to standard chemotherapy.
HealthScience & TechnologyMedical Science DaraxonrasibClinical trialPancreatic cancerChemotherapyMedical researchDrug developmentThe Washington Post